Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-0646
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer ; day:11 ; month:10 ; year:2021 ; pages:1-8
Investigational new drugs ; (11.10.2021), 1-8
- Urheber
-
Nishimura, Ari
Ono, Akira
Wakuda, Kazushige
Kawabata, Takanori
Yabe, Michitoshi
Miyawaki, Taichi
Miyawaki, Eriko
Kodama, Hiroaki
Nishioka, Naoya
Mamesaya, Nobuaki
Kobayashi, Haruki
Omori, Shota
Kenmotsu, Hirotsugu
Naito, Tateaki
Murakami, Haruyasu
Harada, Hideyuki
Takahashi, Toshiaki
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10637-021-01191-6
- URN
-
urn:nbn:de:101:1-2022012118481008819184
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nishimura, Ari
- Ono, Akira
- Wakuda, Kazushige
- Kawabata, Takanori
- Yabe, Michitoshi
- Miyawaki, Taichi
- Miyawaki, Eriko
- Kodama, Hiroaki
- Nishioka, Naoya
- Mamesaya, Nobuaki
- Kobayashi, Haruki
- Omori, Shota
- Kenmotsu, Hirotsugu
- Naito, Tateaki
- Murakami, Haruyasu
- Harada, Hideyuki
- Takahashi, Toshiaki
- SpringerLink (Online service)
Ähnliche Objekte (12)
Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer
Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
The timing of durvalumab administration affects the risk of pneumonitis in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis
Prognostic value of neutrophil to lymphocyte ratio and lymphocyte counts before durvalumab consolidation after radio-chemotherapy in locally advanced non-small cell lung cancer
Durvalumab Consolidation Treatment after Chemoradiotherapy for an HIV-Positive Patient with Locally Advanced Non-Small Cell Lung Cancer
Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer
Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy
Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer
Lethal Immune-Related Pneumonitis after Durvalumab Therapy for Small Cell Lung Cancer: A First Case in China
Arzneimittel Profil Durvalumab
Radiation myelitis after durvalumab administration following chemoradiotherapy for locally advanced non-small cell lung cancer: an illustrative case report and review of the literature
Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer
Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
The timing of durvalumab administration affects the risk of pneumonitis in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis
Prognostic value of neutrophil to lymphocyte ratio and lymphocyte counts before durvalumab consolidation after radio-chemotherapy in locally advanced non-small cell lung cancer
Durvalumab Consolidation Treatment after Chemoradiotherapy for an HIV-Positive Patient with Locally Advanced Non-Small Cell Lung Cancer
Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer
Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy
Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer
Lethal Immune-Related Pneumonitis after Durvalumab Therapy for Small Cell Lung Cancer: A First Case in China
Arzneimittel Profil Durvalumab
Radiation myelitis after durvalumab administration following chemoradiotherapy for locally advanced non-small cell lung cancer: an illustrative case report and review of the literature
Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer
Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
The timing of durvalumab administration affects the risk of pneumonitis in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis
Prognostic value of neutrophil to lymphocyte ratio and lymphocyte counts before durvalumab consolidation after radio-chemotherapy in locally advanced non-small cell lung cancer
Durvalumab Consolidation Treatment after Chemoradiotherapy for an HIV-Positive Patient with Locally Advanced Non-Small Cell Lung Cancer
Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer
Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy
Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer
Lethal Immune-Related Pneumonitis after Durvalumab Therapy for Small Cell Lung Cancer: A First Case in China
Arzneimittel Profil Durvalumab